Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Receivables (2021 - 2025)

Tg Therapeutics (TGTX) has 5 years of Change in Receivables data on record, last reported at $40.2 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 199.03% year-over-year to $40.2 million; the TTM value through Dec 2025 reached $176.4 million, up 125.94%, while the annual FY2025 figure was $176.4 million, 125.94% up from the prior year.
  • Change in Receivables reached $40.2 million in Q4 2025 per TGTX's latest filing, up from $33.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $60.9 million in Q1 2025 and bottomed at -$814000.0 in Q2 2022.
  • Average Change in Receivables over 5 years is $16.1 million, with a median of $11.8 million recorded in 2023.
  • Peak YoY movement for Change in Receivables: tumbled 608.75% in 2022, then soared 24913.64% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $5000.0 in 2021, then tumbled by 1860.0% to -$88000.0 in 2022, then surged by 13478.41% to $11.8 million in 2023, then rose by 14.31% to $13.5 million in 2024, then soared by 199.03% to $40.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $40.2 million in Q4 2025, $33.9 million in Q3 2025, and $41.4 million in Q2 2025.